Kyverna CAR T therapy could become first approved stiff person syndrome treatment

· Science · United States

Science News reports that a CAR T cell therapy from Kyverna Therapeutics could become the first approved treatment for stiff person syndrome if the FDA gives it the green light. CAR T therapy is a form of cell treatment in which a patient's immune cells are engineered to target specific cells, and it is best known in blood cancers; the item frames this as a 'living drug' that could change the course of autoimmune disease. The report does not state the therapy's name, the stage of regulatory review, the trial results or a decision date. Stiff person syndrome is a rare neurological disorder with few dedicated treatments, so an approval would mark the first purpose-built therapy for the condition and a widening of CAR T beyond oncology into autoimmune disease.

Why it matters：A first approval in stiff person syndrome would test whether CAR T can become a commercial platform for autoimmune disease, a question that matters across cell-therapy developers and payers.

Key points

  • The therapy comes from Kyverna Therapeutics
  • It would be the first approved treatment for stiff person syndrome
  • FDA approval has not yet been granted

Sources (original reporting)

More stories from this day